摘要
目的:观察不同剂量辛伐他汀对急性心肌梗死患者近期疗效与安全性。方法:将116例急性心肌梗死患者在常规治疗基础上(包括溶栓药物、硝酸酯类药物、血管紧张素转换酶抑制剂、β受体阻滞剂、阿司匹林、低分子肝素),随机分为常规剂量组:辛伐他汀20mg,每晚1次;高剂量组:辛伐他汀40mg,每晚1次。两组均于急性心肌梗死发病后24h内开始用药,观察30d内主要心血管事件联合终点。结果:治疗30d两组比较,高剂量组明显减少心血管事件联合终点:所有原因死亡,心肌再梗死,不稳定心绞痛,卒中(P<0.05)。结论:对于急性心肌梗死患者,大剂量辛伐他汀在降低主要心血管事件方面的作用优于常规剂量辛伐他汀,且具有良好的安全性。
Objective: To investigate the efficacy and safety of Simvastatin with two different doses in treating acute myocardial infarction. Methods: 116 patients with AMI were randomly divided into two groups. They were treated with Simvastatin 20mg and 40mg a day respectively and were followed up for 30 days. The effect of Simvastatin with two different doses on incidence of cardiac vascular events and its side effect were observed. Results.. During the 30 days' following up,the incidence of cardiac vascular events in 40mg group was significantly lower than that in 20mg group (P〈0.05). Conclusion: The efficacy of 40mg Simvastatin is superior to that of 20mg Simvastatin in decreasing the incidence of cardiac vascular events.
出处
《河北北方学院学报(医学版)》
2006年第4期29-31,共3页
Journal of Hebei North University:Medical Edition
关键词
辛伐他汀
急性
心肌梗死
剂量
Simvastatin
Acute
Myocardial infarction
Dosage